Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel pharmacological agents in clinical development for solid tumours.

G K Dy1, P Haluska, A A Adjei

  • 1Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Expert Opinion on Investigational Drugs
|January 5, 2002
PubMed
Summary

Traditional cancer treatments using DNA-damaging agents have limitations. Novel molecular targets and therapeutic agents are emerging, offering new hope for effective cancer treatment with reduced toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors.

ESMO open·2025
Same author

Sex differences in the pharmacokinetics of anticancer drugs: a systematic review.

ESMO open·2024
Same author

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.

ESMO open·2023
Same author

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Female leadership in oncology-has progress stalled? Data from the ESMO W4O authorship and monitoring studies.

ESMO open·2021
Same author

Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.

Gynecologic oncology·2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer therapy has historically relied on DNA-directed cytotoxic agents.
  • These traditional methods often exhibit limited efficacy and substantial toxicity.
  • Recent breakthroughs in tumor biology have identified novel molecular targets.

Purpose of the Study:

  • To review recent advances in cancer therapy.
  • To discuss novel molecular targets and therapeutic agents.
  • To highlight agents targeting key cancer pathways currently in clinical trials.

Main Methods:

  • Literature review of recent advances in cancer therapy.
  • Analysis of novel molecular targets in cancer pathogenesis.
  • Discussion of therapeutic agents targeting signal transduction, cell cycle, angiogenesis, and apoptosis.

Related Experiment Videos

Main Results:

  • Identification of novel molecular targets in cancer progression.
  • Emergence of promising therapeutic agents in clinical testing.
  • Focus on targeted therapies with potentially improved efficacy and reduced toxicity.

Conclusions:

  • Novel therapeutic strategies targeting specific molecular pathways represent a paradigm shift in cancer treatment.
  • Targeted agents show promise for more effective and less toxic cancer therapies.
  • The review highlights the potential of these new agents in clinical practice.